Recent Research Analysts’ Ratings Changes for Moderna (MRNA)

Several analysts have recently updated their ratings and price targets for Moderna (NASDAQ: MRNA):

• 10/27/2026 – Moderna was downgraded by William Blair from “outperform” to “market perform”.
• 10/26/2026 – Moderna had its “overweight” rating reaffirmed by Piper Sandler. They now have a $230.00 price target on the stock, up from $167.00.
• 10/23/2026 – Moderna had its “sell” rating reaffirmed by Citigroup.
• 10/21/2026 – Moderna had its “buy” rating reaffirmed by TD Cowen.
• 10/21/2026 – Moderna had its price target raised by TD Cowen from $40.00 to $90.00. They now have a “hold” rating on the stock.
• 10/15/2026 – Moderna had its price target raised by The Goldman Sachs Group from $120.00 to $137.00. They now have a “neutral” rating on the stock.
• 10/9/2026 – Moderna had its price target raised by Bank of America from $170.00 to $200.00. They now have a “neutral” rating on the stock.
• 10/8/2026 – Moderna had its price target raised by Evercore from $50.00 to $80.00.
• 10/7/2026 – Moderna had its price target raised by Morgan Stanley from $89.00 to $95.00. They now have an “equal weight” rating on the stock.
• 9/30/2026 – Moderna was downgraded by Citigroup from “neutral” to “sell”. They now have a $80.00 price target on the stock, up from $60.00.
• 9/25/2026 – Moderna had its “market perform” rating reaffirmed by Sanford C. Bernstein.
• 9/23/2026 – Moderna was upgraded by Singular Research to “hold”.
• 9/22/2026 – Moderna had its “neutral” rating reaffirmed by UBS Group.
• 9/11/2026 – Moderna had its price target raised by Berenberg Bank from $45.00 to $100.00. They now have a “hold” rating on the stock.
• 9/9/2026 – Moderna had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/3/2026 – Moderna was given a new $81.00 price target by UBS Group.
• 9/3/2026 – Moderna was downgraded by UBS Group from “hold” to “sell”.
• 9/3/2026 – Moderna was downgraded by Rothschild & Co Redburn from “neutral” to “sell”. They now have a $81.00 price target on the stock, up from $40.00.

Insiders Place Their Bets

In related news, CFO James M. Mock sold 34,836 shares of Moderna stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the sale, the chief financial officer owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the business’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider owned 74,129 shares in the company, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 197,251 shares of company stock worth $33,875,904. Corporate insiders own 10.80% of the company’s stock.

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.